300639 Guangdong Hybribio Biotech
- 5.13
- +0.08+1.58%
Guangdong Hybribio Biotech News
Capbio (300639): Clear base and go to battle lightly
Cape Biotech (300639): Steady resumption of routine business and rapid release of innovative products such as HPV screening
Cape Biotech (300639): Demand is improving season by season, HPV screening certificates help expand business
Cape Biotech (300639) 2022 semi-annual report review: The volume of HPV and other products is significant and the leader in molecular diagnosis is growing rapidly
CapBio (300639): Steady growth of conventional molecular diagnostic products actively promotes the expansion of HPV testing business
Research Report Nuggets | Anxin Securities: Capo Biotech products are leading in many fields, and ten joint inspection products are expected to drive volume
Capbiotech (300639): Self-produced molecular diagnostic reagents achieve steady growth, awaiting full recovery of routine business
Capbiotech (300639): Achieved a high increase in revenue of 109%, expanding internal research and external expansion to build a molecular diagnosis ecosystem
Capbiotech (300639) 2022 Annual Report Review: Performance is in line with expectations, regular business is expected to continue to grow rapidly
Capbiotech (300639): Seize historical opportunities and continued high growth in performance
Capbiotech (300639): The medical testing service business continues to grow, with performance exceeding expectations
Capcom Biology (300639): The integrated strategic business of “nucleic acid testing products+medical testing services” is developing rapidly
Kip Biology (300639): sustained high growth in performance, R & D plus provides the source power for long-term development.
Kip Biology (300639): outstanding performance of molecular diagnostic leader COVID-19 nucleic acid detection continues to increase
Kepp Biology (300639): Q1 epidemic repeated Nucleic Acid testing Service drives High growth
Kip Biology (300639): COVID-19 Nucleic Acid testing demand upsurge performance achieved 191% higher-than-expected growth
Kip Biology (300639): COVID-19 's achievements in epidemic prevention and control made significant progress in the construction of medical laboratories.
Kip Biology (300639): driven by the dual Strategy of COVID-19 Test full
Kip Biology (300639): the performance is in line with expectations and COVID-19 nucleic acid detection continues to achieve high growth.
Kip Biology (300639): "COVID-19 testing volume + conventional product recovery" helps performance high growth and scale effect significantly boosts profitability
Analysis
Price Target
No Data
